Understanding how genetic changes in bladder cancer affect treatment resistance
Official title: Targeting APOBEC3A-induced genetic heterogeneity and drug resistance in bladder cancer
Funded at Weill Medical Coll of Cornell Univ · NIH-10932366 · Data updated 2026-11-12
This study is looking at how a protein called APOBEC3A affects the way bladder cancer cells change and become resistant to treatments, with the goal of finding better ways to target these tough cancer cells and improve outcomes for patients.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 20, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $466,426 |
| NIH project number | 5R37CA279737-02 |
| Project ID | NIH-10932366 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with advanced urothelial carcinoma who are experiencing treatment resistance.
✕Less likely to help
Patients with early-stage bladder cancer or those who do not have urothelial carcinoma may not benefit from this research.
What this research studies
This research investigates the role of a specific protein, APOBEC3A, in causing genetic diversity within bladder cancer cells, which can lead to resistance against treatments. By examining how this protein contributes to the emergence of resistant cancer cell subclones, the research aims to identify new strategies to target these vulnerabilities. The approach includes studying patient-derived organoids and cell lines to uncover the mechanisms behind this resistance and develop precision therapies that could improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for bladder cancer patients by overcoming drug resistance.
How similar studies have gone: Previous research has shown promising results in targeting genetic heterogeneity in cancers, suggesting that this approach could be effective.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Faltas, Bishoy Morris — Weill Medical Coll of Cornell Univ
- Study coordinator: Faltas, Bishoy Morris
Related research
Other NIH-funded projects on the same topics.
-
Population modeling to reduce bladder cancer burden
Aimed at predicting and guiding effective, population-based ways to prevent and control bladder cancer.
-
Blocking a new immune checkpoint in bladder cancer
Researchers are trying medicines that block a newly found immune pathway to help people with bladder cancer, especially those whose tumors do not respond to current immunotherapy.
-
Nrf2 in T cells and how it could boost immune power against bladder cancer
A small grant will explore how a T-cell protein called Nrf2 affects muscle-invasive bladder cancer and whether targeting it could help patients respond better to immune therapies.
-
Understanding why bladder cancer spreads and resists treatment
This grant studies how advanced bladder cancer changes and spreads across the body, aiming to uncover why it’s hard to treat.
-
Molecular clues to bladder cancer cell changes and therapy response
This NIH grant looks at how bladder cancer cells change their identity and how that affects response to treatment, with a focus on aggressive neuroendocrine variants.
-
Repurposing spironolactone to treat bladder cancer inside the bladder
Aims to repurpose spironolactone as an intravesical treatment for non-muscle invasive bladder cancer to help prevent recurrence and progression.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.